Author: Ken Dropiewski

NeuroVasc Technologies, Inc. closes Series B financing of $6.3MM

LAGUNA HILLS, Calif., May 16, 2018 /PRNewswire/ — NeuroVasc Technologies, Inc., a medical device company active in the endovascular field, announced today that it has closed a $6.3MM Series B Preferred Stock financing.  The funding includes multiple investors and was led by ShangBay Capital. NeuroVasc Technologies, Inc. is dedicated to improving treatment of […]

CareTaker Medical Completes $3.4M Investment to Expand Sales of Wireless “Beat-by-Beat” Continuous Blood Pressure and Vital Signs Monitor

CHARLOTTESVILLE, Va., May 16, 2018 /PRNewswire/ — CareTaker Medical, LLC, an innovator in Continuous Non-Invasive Blood Pressure and wireless Vital Signs monitoring today announced completion of a $3.4M investment round led by IrishAngels, KOFA Healthcare and Jaffray Woodriff (executed by his family office, Felton Group, LLC), with participation from both new and existing individual investors.  Proceeds will accelerate the […]

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

THOUSAND OAKS, Calif., May 16, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels. With the […]

Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease

DUBLIN – May 16, 2018 – Medtronic plc (NYSE: MDT) today announced the initiation of a clinical study in the U.S. to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions, which account for approximately 20 percent of all percutaneous coronary interventions (PCI).1 The Bifurcation Cohort, […]

Boston Scientific Announces Schedule of Presentations at EuroPCR 2018

MARLBOROUGH, Mass., May 16, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the schedule of key presentations, including two late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program, in Paris, on May 22-25. During the late-breaking sessions on Wednesday, May 23, data from the RESPOND trial will provide two-year, ‘real world’ […]

Pi-Cardia Initiates First-in-Human Study With Novel Non-Implant Based Treatment of Aortic Stenosis

REHOVOT, Israel, May 16, 2018 /PRNewswire/ –Pi-Cardia Ltd., announced today that it recently started its First-in-Human study with its Leaflex(TM) Performer catheter system. The Leaflex(TM) Performer is a trans-femoral catheter that uses two unique mechanical structures for scoring valve calcification at multiple locations, restoring leaflets flexibility and improving valve hemodynamics. […]

The FH Foundation® Begins Enrollment in PAGENT Study to Improve Understanding of Genetic Testing for Familial Hypercholesterolemia (FH)

PASADENA, Calif., May 16, 2018–  The FH Foundation, a leading research and advocacy organization, today announced the launch of a new research study that aims to understand the willingness for individuals with a clinical diagnosis of familial hypercholesterolemia (FH) and their family members to undergo confirmatory genetic testing, through a […]

RenalGuard Solutions Announces Appointment of Dr. Howard R. Levin as Chief Medical Officer

MILFORD, Mass.–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced that Howard R. Levin, M.D., has been named the company’s chief medical officer. A veteran in the field of biomedical engineering and cardiology and one of the original developers […]